We can support you and your company with efficient, key-in hand Pricing and Market Access services that you as our client, as a patient, a physician, as health technology evaluator and a decision maker in the healthcare environment will regard as creative, focused, valuable and excellent.

Service offerings for your benefit:

  • Strategic analysis of environmental information
  • EU-5 market access and pricing strategies
  • Requests for advice meetings with HTA and regulatory agencies
  • Evidence generation and review
  • Reimbursement file submissions
  • Scientific (MA) Dossier writing
  • Stakeholder engagement plans and activities (sounding boards, campaigning etc.)
  • Pricing research & value demonstration services
  • Cost-effectiveness modelling
  • Price negotiation support
  • Contracting with payers
  • Wholesale license and distribution
  • Listing in transparency lists
  • Early Access Programs
  • Collection and analysis of real-world evidence
  • Multicriteria Decision Analysis (MCDA)


The answer to the How?

Our consulting approach builds on your studies and evidence, and integrates the value drivers and market access experiences into one strategy.

Discover more

Market Access

The ‘perfect market access‘ or the ‘perfect storm’!

European market access challenges usually have acronyms: NICE, HAS, AMNOG, AIFA and CIMP – which give evidence of the global megatrend for rigorous assessments in reimbursement decisions of health technologies (Health Technology Assessment (HTA)).

Discover more


Value determination, demonstration and communication.

It is not simply a question of determining how much payers will pay for drugs. It is a question, of how much of the value can you demonstrate within the clinical trial results, and how much clinical and economic justification do you have to supplement from other evidence sources.

Discover more